NO961075L - Krystallinsk, vannfritt mykofenolatmofetil og intravenöst preparat derav - Google Patents

Krystallinsk, vannfritt mykofenolatmofetil og intravenöst preparat derav

Info

Publication number
NO961075L
NO961075L NO961075A NO961075A NO961075L NO 961075 L NO961075 L NO 961075L NO 961075 A NO961075 A NO 961075A NO 961075 A NO961075 A NO 961075A NO 961075 L NO961075 L NO 961075L
Authority
NO
Norway
Prior art keywords
mycophenolate mofetil
crystalline
intravenous preparation
anhydrous mycophenolate
anhydrous
Prior art date
Application number
NO961075A
Other languages
English (en)
Other versions
NO961075D0 (no
NO314727B1 (no
Inventor
Roger Cherng Fu
De-Mei Leung
Jeffrey S Fleitman
Michele C Rizzolio
Original Assignee
Syntex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex Inc filed Critical Syntex Inc
Publication of NO961075D0 publication Critical patent/NO961075D0/no
Publication of NO961075L publication Critical patent/NO961075L/no
Publication of NO314727B1 publication Critical patent/NO314727B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Furan Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
NO19961075A 1993-09-15 1996-03-15 Krystallinsk, vannfritt mykofenolatmofetil, intravenöst preparat derav, fremgangsmåter for fremstilling av preparat og formulering,anvendelse av forbindelsen til fremstilling av et medikament, samt sett anvendelig forfremstilling avintravenös NO314727B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12184193A 1993-09-15 1993-09-15
PCT/US1994/010142 WO1995007902A1 (en) 1993-09-15 1994-09-12 Crystalline anhydrous mycophenolate mofetil and intravenous formulation thereof

Publications (3)

Publication Number Publication Date
NO961075D0 NO961075D0 (no) 1996-03-15
NO961075L true NO961075L (no) 1996-03-15
NO314727B1 NO314727B1 (no) 2003-05-12

Family

ID=22399119

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19961075A NO314727B1 (no) 1993-09-15 1996-03-15 Krystallinsk, vannfritt mykofenolatmofetil, intravenöst preparat derav, fremgangsmåter for fremstilling av preparat og formulering,anvendelse av forbindelsen til fremstilling av et medikament, samt sett anvendelig forfremstilling avintravenös

Country Status (31)

Country Link
US (2) US5543408A (no)
EP (1) EP0724581B1 (no)
JP (1) JP3411038B2 (no)
KR (1) KR100349772B1 (no)
CN (1) CN1060770C (no)
AT (1) ATE173475T1 (no)
AU (1) AU677435B2 (no)
BR (1) BR9407469A (no)
CA (1) CA2171836C (no)
CZ (1) CZ292423B6 (no)
DE (1) DE69414720T2 (no)
DK (1) DK0724581T3 (no)
ES (1) ES2123831T3 (no)
FI (1) FI119639B (no)
HU (1) HU217300B (no)
IL (1) IL110970A (no)
LT (1) LT4052B (no)
LV (1) LV11326B (no)
MX (1) MXPA94007099A (no)
NO (1) NO314727B1 (no)
NZ (1) NZ273801A (no)
PH (1) PH30685A (no)
PL (1) PL178522B1 (no)
RO (2) RO118075B1 (no)
RU (1) RU2132849C1 (no)
SG (1) SG55006A1 (no)
SI (1) SI9420052B (no)
TW (1) TW370527B (no)
UA (1) UA49797C2 (no)
WO (1) WO1995007902A1 (no)
ZA (1) ZA947088B (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9512854D0 (en) * 1995-06-23 1995-08-23 Wellcome Found Novel formulation
IN188985B (no) * 1998-12-09 2002-11-30 Biocon Ltd
CZ292123B6 (cs) * 2001-06-08 2003-08-13 Ivax Pharmaceuticals S.R.O. Způsob přípravy mykofenolátu mofetilu
GB0301259D0 (en) 2003-01-20 2003-02-19 Novartis Ag Organic compounds
GB0307553D0 (en) * 2003-04-01 2003-05-07 Novartis Ag Organic compounds
US20050187170A1 (en) * 2003-06-16 2005-08-25 Biocryst Pharmaceuticals, Inc. Enhancing the efficiency of RNA polymerase inhibitors by using inosine monophosphate dehydrogenase inhibitors
ES2308226T3 (es) * 2003-09-11 2008-12-01 Sandoz Ag Proceso para la produccion de micofenolato mofetil.
MXPA06005659A (es) * 2004-04-26 2007-04-10 Teva Gyogyszergyar Zartkoruen Proceso para preparacion de acido micofenolico y derivados de ester del mismo.
WO2005105771A1 (en) * 2004-04-27 2005-11-10 Teva Gyógyszergyár Zàrtköruen Muködo Rèszvènytàrsasàg Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
US20060069150A1 (en) * 2004-07-20 2006-03-30 Sandor Molnar Processes for preparation of crystalline mycophenolate sodium
CN100383520C (zh) * 2004-09-20 2008-04-23 复旦大学 一种测定人血浆中霉酚酸及其代谢物的方法
WO2006086500A2 (en) * 2005-02-08 2006-08-17 Aspreva Pharmaceuticals Sa Compositions and methods for treating vascular, autoimmune and inflammatory diseases
US20060235009A1 (en) * 2005-02-08 2006-10-19 Richard Glickman Treatment of vascular, autoimmune and inflammatory diseases using low dosages of IMPDH inhibitors
US20080280977A1 (en) * 2005-04-26 2008-11-13 Sandor Molnar Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid
WO2008000418A2 (en) 2006-06-27 2008-01-03 Sandoz Ag New method for salt preparation
CN101953807A (zh) * 2010-10-09 2011-01-26 山西普德药业有限公司 一种注射用吗替麦考酚酯冻干粉针剂及其制备方法
BR112015022854A2 (pt) 2013-03-14 2017-07-18 Alkermes Pharma Ireland Ltd pró-farmacos de fumaratos e uso do mesmo no tratamento de várias doenças
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
US9168246B2 (en) 2013-06-27 2015-10-27 Veloxis Pharmaceutical A/S Regimen for suppressing organ rejection
JP6337135B2 (ja) 2014-02-24 2018-06-06 アルカーメス ファーマ アイルランド リミテッド フマル酸エステルのスルホンアミドプロドラッグ及びスルフィンアミドプロドラッグ並びに種々の疾患の治療におけるその使用
US11918684B2 (en) 2017-03-13 2024-03-05 Liqmeds Worldwide Limited Pharmaceutical composition of oral suspension of immunosuppressive agents
WO2020039263A2 (en) 2018-08-18 2020-02-27 Ftf Pharma Private Limited Pharmaceutical suspension for oral dosage
CA3212370A1 (en) 2021-03-03 2022-09-09 Sana Biotechnology, Inc. Immunosuppressive therapies for use with cardiomyocyte cell therapies, and associated methods and compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4328213A (en) * 1979-11-28 1982-05-04 Schering Corporation Stable injectable labetalol formulation
US4478829A (en) * 1983-04-28 1984-10-23 Armour Pharmaceutical Company Pharmaceutical preparation containing purified fibronectin
SU1170760A1 (ru) * 1984-02-20 1996-09-20 Ф.Ю. Рачинский Дигидробромид 2-(2-морфолиноэтилтио)бензимидазола, повышающий физическую работоспособность и ускоряющий процессы восстановления после физических нагрузок и длительного стресса
US4753935A (en) * 1987-01-30 1988-06-28 Syntex (U.S.A.) Inc. Morpholinoethylesters of mycophenolic acid and pharmaceutical compositions
FR2653999A1 (fr) * 1989-11-06 1991-05-10 Adir Nouveaux derives de la morpholine, leur procede de preparation et les compositions pharmaceutiques les renfermant.

Also Published As

Publication number Publication date
HU217300B (hu) 1999-12-28
WO1995007902A1 (en) 1995-03-23
JP3411038B2 (ja) 2003-05-26
IL110970A0 (en) 1994-11-28
CN1060770C (zh) 2001-01-17
AU7723894A (en) 1995-04-03
HU9600652D0 (en) 1996-05-28
FI961169A0 (fi) 1996-03-13
NZ273801A (en) 1997-10-24
CA2171836C (en) 2006-11-14
DK0724581T3 (da) 1999-08-02
TW370527B (en) 1999-09-21
NO961075D0 (no) 1996-03-15
DE69414720D1 (de) 1998-12-24
CN1131420A (zh) 1996-09-18
JPH09502721A (ja) 1997-03-18
HK1012624A1 (en) 1999-08-06
LT4052B (en) 1996-10-25
UA49797C2 (uk) 2002-10-15
CZ78896A3 (en) 1996-10-16
CA2171836A1 (en) 1995-03-23
FI119639B (fi) 2009-01-30
RO118075B1 (ro) 2003-01-30
BR9407469A (pt) 1996-11-12
ZA947088B (en) 1996-03-14
IL110970A (en) 1999-01-26
US5543408A (en) 1996-08-06
KR100349772B1 (ko) 2002-12-28
AU677435B2 (en) 1997-04-24
FI961169L (fi) 1996-03-13
LT96028A (en) 1996-08-26
PL178522B1 (pl) 2000-05-31
LV11326A (lv) 1996-06-20
RU2132849C1 (ru) 1999-07-10
CZ292423B6 (cs) 2003-09-17
SG55006A1 (en) 1998-12-21
DE69414720T2 (de) 1999-04-08
ES2123831T3 (es) 1999-01-16
HUT75119A (en) 1997-04-28
PL313480A1 (en) 1996-07-08
EP0724581B1 (en) 1998-11-18
RO118427B1 (ro) 2003-05-30
MXPA94007099A (es) 2004-01-23
EP0724581A1 (en) 1996-08-07
PH30685A (en) 1997-09-16
NO314727B1 (no) 2003-05-12
SI9420052A (en) 1996-12-31
ATE173475T1 (de) 1998-12-15
SI9420052B (sl) 2004-02-29
US5545637A (en) 1996-08-13
LV11326B (en) 1996-10-20

Similar Documents

Publication Publication Date Title
NO961075L (no) Krystallinsk, vannfritt mykofenolatmofetil og intravenöst preparat derav
NO971889L (no) Forbindelser og sammensetninger for levering av aktive midler
DE69427704D1 (de) Neue (r)-5-carbamoyl-8-fluor-3-n,n-disubstituierte-amino-3,4-dihydro-2h-1-benzopyrane
LU88217I2 (no)
DE69104991D1 (de) Mometason-furoate-monohydrat, verfahren zu seiner herstellung und das enthaltende pharmazeutische zusammensetzungen.
CA2171275A1 (en) Stilbene derivatives and pharmaceutical compositions containing them
CA2108903A1 (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
ZA922297B (en) Crystalline tiababine monohydrate,its preparation and use
RU94031161A (ru) Фармацевтическая композиция и способ ее получения, способ лечения нарушений, развивающихся вследствие нейродегенеративных процессов
GEP20032953B (en) Antitumor Agents
DE68929368D1 (de) Cephemderivate und Verfahren zu ihrer Herstellung
TW252979B (no)
ATE35812T1 (de) Gamma-butyrolactonderivate, verfahren zur herstellung derselben und dieselben als aktive bestandteile enthaltende immunomodulierende zubereitungen.
IT8022843A0 (it) Sali di endo-8-metil-8-sin-alchil-8-azoniabiciclo aperta par. quadrata 3.2.1.chiusa par.quadrata-ottan-3-alchilcarbossilati , processo per la loro preparazione e composizioni terapeutiche che li contengono come principio attivo.
WO1990003172A3 (en) Bile acids for treatment of viral infections
RU94021365A (ru) Производные метилпиперазиназепина, способ их получения, фармацевтическая композиция на их основе и использование производных в качестве фармацевтически активного вещества
IE840977L (en) Pharmaceutical preparations
GEP20033054B (en) 2,4,4-Trisubstituted-1,3-Dioxolane Antifungals
IT8124405A0 (it) Derivato dell'indoprofene, processo per la sua preparazione e composizioni terapeutiche che lo comprendono come principio attivo.
ES2076517T3 (es) Ergolinas disustituidas en posiciones 2,13, su preparacion y utilizacion en medicamentos.
MX9605668A (es) Sal de estilbazolio, su preparacion y uso.

Legal Events

Date Code Title Description
MK1K Patent expired